On Friday, Lexeo Therapeutics Inc. (NASDAQ: LXEO) opened higher 22.20% from the last session, before settling in for the closing price of $9.10. Price fluctuations for LXEO have ranged from $7.86 to $22.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 19.69% over the last five years. Company’s average yearly earnings per share was noted 77.70% at the time writing. With a float of $21.98 million, this company’s outstanding shares have now reached $26.65 million.
The firm has a total of 58 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Lexeo Therapeutics Inc. (LXEO) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Lexeo Therapeutics Inc. is 33.51%, while institutional ownership is 66.07%. The most recent insider transaction that took place on Oct 10 ’24, was worth 40,496. In this transaction Chief Executive Officer of this company sold 5,000 shares at a rate of $8.10, taking the stock ownership to the 120,695 shares. Before that another transaction happened on Sep 10 ’24, when Company’s Chief Executive Officer sold 5,000 for $10.65, making the entire transaction worth $53,274. This insider now owns 120,695 shares in total.
Lexeo Therapeutics Inc. (LXEO) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -12.36 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -2.6) by -9.76. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.7 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 77.70% per share during the next fiscal year.
Lexeo Therapeutics Inc. (NASDAQ: LXEO) Trading Performance Indicators
Check out the current performance indicators for Lexeo Therapeutics Inc. (LXEO). In the past quarter, the stock posted a quick ratio of 9.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.71, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.77 in one year’s time.
Technical Analysis of Lexeo Therapeutics Inc. (LXEO)
Analysing the last 5-days average volume posted by the [Lexeo Therapeutics Inc., LXEO], we can find that recorded value of 0.35 million was better than the volume posted last year of 0.21 million. As of the previous 9 days, the stock’s Stochastic %D was 90.81%. Additionally, its Average True Range was 0.71.
During the past 100 days, Lexeo Therapeutics Inc.’s (LXEO) raw stochastic average was set at 28.01%, which indicates a significant decrease from 98.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 107.21% in the past 14 days, which was higher than the 93.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.25, while its 200-day Moving Average is $13.63. Now, the first resistance to watch is $11.83. This is followed by the second major resistance level at $12.54. The third major resistance level sits at $13.92. If the price goes on to break the first support level at $9.75, it is likely to go to the next support level at $8.37. Should the price break the second support level, the third support level stands at $7.66.
Lexeo Therapeutics Inc. (NASDAQ: LXEO) Key Stats
There are currently 32,945K shares outstanding in the company with a market cap of 367.63 million. Presently, the company’s annual sales total 0 K according to its annual income of -66,390 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -21,240 K.
